ID   BTK_HUMAN               Reviewed;         659 AA.
AC   Q06187; Q32ML5;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   05-OCT-2010, entry version 144.
DE   RecName: Full=Tyrosine-protein kinase BTK;
DE            EC=2.7.10.2;
DE   AltName: Full=Agammaglobulinaemia tyrosine kinase;
DE            Short=ATK;
DE   AltName: Full=B-cell progenitor kinase;
DE            Short=BPK;
DE   AltName: Full=Bruton tyrosine kinase;
GN   Name=BTK; Synonyms=AGMX1, ATK, BPK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=93140868; PubMed=8380905; DOI=10.1038/361226a0;
RA   Vetrie D., Vorechovsky I., Sideras P., Holland J., Davies A.,
RA   Flinter F., Hammarstroem L., Kinnon C., Levinsky R.J., Bobrow M.,
RA   Smith C.I.E., Bentley D.R.;
RT   "The gene involved in X-linked agammaglobulinaemia is a member of the
RT   src family of protein-tyrosine kinases.";
RL   Nature 361:226-233(1993).
RN   [2]
RP   ERRATUM.
RA   Vetrie D., Vorechovsky I., Sideras P., Holland J., Davies A.,
RA   Flinter F., Hammarstroem L., Kinnon C., Levinsky R.J., Bobrow M.,
RA   Smith C.I.E., Bentley D.R.;
RL   Nature 364:362-362(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   MEDLINE=94377492; PubMed=8090769; DOI=10.1073/pnas.91.19.9062;
RA   Ohta Y., Haire R.N., Litman R.T., Fu S.M., Nelson R.P., Kratz J.,
RA   Kornfeld S.J., la Morena M., Good R.A., Litman G.W.;
RT   "Genomic organization and structure of Bruton agammaglobulinemia
RT   tyrosine kinase: localization of mutations associated with varied
RT   clinical presentations and course in X chromosome-linked
RT   agammaglobulinemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:9062-9066(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=95012452; PubMed=7927535; DOI=10.1007/BF01246672;
RA   Rohrer J., Parolini O., Belmont J.W., Conley M.E.;
RT   "The genomic structure of human BTK, the defective gene in X-linked
RT   agammaglobulinemia.";
RL   Immunogenetics 40:319-324(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS XLA SER-334; ARG-506;
RP   GLN-520; TRP-562 AND LYS-630.
RX   MEDLINE=95152493; PubMed=7880320; DOI=10.1093/hmg/3.10.1743;
RA   Hagemann T.L., Chen Y., Rosen F.S., Kwan S.-P.;
RT   "Genomic organization of the Btk gene and exon scanning for mutations
RT   in patients with X-linked agammaglobulinemia.";
RL   Hum. Mol. Genet. 3:1743-1749(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=95352959; PubMed=7626884; DOI=10.1007/BF00364796;
RA   Oeltjen J.C., Liu X., Lu J., Allen R.C., Muzny D.M., Belmont J.W.,
RA   Gibbs R.A.;
RT   "Sixty-nine kilobases of contiguous human genomic sequence containing
RT   the alpha-galactosidase A and Bruton's tyrosine kinase loci.";
RL   Mamm. Genome 6:334-338(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE OF 1-442.
RX   MEDLINE=93145329; PubMed=8425221; DOI=10.1016/0092-8674(93)90667-F;
RA   Tsukada S., Saffran D.C., Rawlings D.J., Parolini O., Allen R.C.,
RA   Klisak I., Sparkes R.S., Kubagawa H., Mohandas T., Quan S.,
RA   Belmont J.W., Cooper M.D., Conley M.E., Witte O.N.;
RT   "Deficient expression of a B cell cytoplasmic tyrosine kinase in human
RT   X-linked agammaglobulinemia.";
RL   Cell 72:279-290(1993).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-12 AND 323-332, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RA   Bienvenut W.V., Claeys D.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [11]
RP   PROTEIN SEQUENCE OF 219-235, AND PHOSPHORYLATION AT TYR-223.
RX   PubMed=12573241; DOI=10.1016/S1570-9639(02)00524-1;
RA   Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A.,
RA   Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.;
RT   "Identification of phosphorylation sites within the SH3 domains of Tec
RT   family tyrosine kinases.";
RL   Biochim. Biophys. Acta 1645:123-132(2003).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF GTF2I, PHOSPHORYLATION AT TYR-223 AND
RP   TYR-551, AND MUTAGENESIS OF GLU-41; PRO-189; TYR-223; TRP-251; ARG-307
RP   AND TYR-551.
RX   MEDLINE=97165069; PubMed=9012831; DOI=10.1073/pnas.94.2.604;
RA   Yang W., Desiderio S.;
RT   "BAP-135, a target for Bruton's tyrosine kinase in response to B cell
RT   receptor engagement.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:604-609(1997).
RN   [13]
RP   INTERACTION WITH IBTK, AND ENZYME REGULATION.
RX   PubMed=11577348; DOI=10.1038/ni1001-939;
RA   Liu W., Quinto I., Chen X., Palmieri C., Rabin R.L., Schwartz O.M.,
RA   Nelson D.L., Scala G.;
RT   "Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding
RT   protein.";
RL   Nat. Immunol. 2:939-946(2001).
RN   [14]
RP   MUTAGENESIS OF 251-TRP-TRP-252, AND INTERACTION WITH SH3BP5.
RX   MEDLINE=98238637; PubMed=9571151; DOI=10.1006/bbrc.1998.8420;
RA   Matsushita M., Yamadori T., Kato S., Takemoto Y., Inazawa J., Baba Y.,
RA   Hashimoto S., Sekine S., Arai S., Kunikata T., Kurimoto M.,
RA   Kishimoto T., Tsukada S.;
RT   "Identification and characterization of a novel SH3-domain binding
RT   protein, Sab, which preferentially associates with Bruton's tyrosine
RT   kinase (Btk).";
RL   Biochem. Biophys. Res. Commun. 245:337-343(1998).
RN   [15]
RP   INTERACTION WITH GTF2I AND ARID3A, AND FUNCTION.
RX   PubMed=16738337; DOI=10.1128/MCB.02009-05;
RA   Rajaiya J., Nixon J.C., Ayers N., Desgranges Z.P., Roy A.L.,
RA   Webb C.F.;
RT   "Induction of immunoglobulin heavy-chain transcription through the
RT   transcription factor Bright requires TFII-I.";
RL   Mol. Cell. Biol. 26:4758-4768(2006).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-551, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-20; SER-21; SER-55;
RP   SER-179; SER-180; THR-191; TYR-223; SER-309; SER-323; SER-342;
RP   TYR-361; TYR-375; TYR-551; THR-602; SER-604 AND SER-659, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 1-170.
RX   MEDLINE=97361821; PubMed=9218782; DOI=10.1093/emboj/16.12.3396;
RA   Hyvoenen M., Saraste M.;
RT   "Structure of the PH domain and Btk motif from Bruton's tyrosine
RT   kinase: molecular explanations for X-linked agammaglobulinaemia.";
RL   EMBO J. 16:3396-3404(1997).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1-170.
RX   MEDLINE=99216540; PubMed=10196129; DOI=10.1016/S0969-2126(99)80057-4;
RA   Baraldi E., Carugo K.D., Hyvoenen M., Surdo P.L., Riley A.M.,
RA   Potter B.V.L., O'Brien R., Ladbury J.E., Saraste M.;
RT   "Structure of the PH domain from Bruton's tyrosine kinase in complex
RT   with inositol 1,3,4,5-tetrakisphosphate.";
RL   Structure 7:449-460(1999).
RN   [21]
RP   STRUCTURE BY NMR OF 209-275.
RX   MEDLINE=98153176; PubMed=9485443; DOI=10.1021/bi972409f;
RA   Hansson H., Mattsson P.T., Allard P., Haapaniemi P., Vihinen M.,
RA   Smith C.I.E., Haerd T.;
RT   "Solution structure of the SH3 domain from Bruton's tyrosine kinase.";
RL   Biochemistry 37:2912-2924(1998).
RN   [22]
RP   REVIEW ON VARIANTS XLA.
RX   MEDLINE=96174621; PubMed=8594569; DOI=10.1093/nar/24.1.160;
RA   Vihinen M., Iwata T., Kinnon C., Kwan S.-P., Ochs H.D.,
RA   Vorechovsky I., Smith C.I.E.;
RT   "BTKbase, mutation database for X-linked agammaglobulinemia (XLA).";
RL   Nucleic Acids Res. 24:160-165(1996).
RN   [23]
RP   REVIEW ON VARIANTS XLA.
RX   MEDLINE=97169387; PubMed=9016530; DOI=10.1093/nar/25.1.166;
RA   Vihinen M., Belohradsky B.H., Haire R.N., Holinski-Feder E.,
RA   Kwan S.-P., Lappalainen I., Lehvaeslaiho H., Lester T., Meindl A.,
RA   Ochs H.D., Ollila J., Vorechovsky I., Weiss M., Smith C.I.E.;
RT   "BTKbase, mutation database for X-linked agammaglobulinemia (XLA).";
RL   Nucleic Acids Res. 25:166-171(1997).
RN   [24]
RP   INVOLVEMENT IN XLA-IGHD.
RX   PubMed=8013627; DOI=10.1016/0014-5793(94)00457-9;
RA   Duriez B., Duquesnoy P., Dastot F., Bougneres P., Amselem S.,
RA   Goossens M.;
RT   "An exon-skipping mutation in the btk gene of a patient with X-linked
RT   agammaglobulinemia and isolated growth hormone deficiency.";
RL   FEBS Lett. 346:165-170(1994).
RN   [25]
RP   VARIANTS XLA TRP-288; GLY-307; ASP-607 AND
RP   SER-VAL-PHE-SER-SER-THR-ARG-103 INS.
RX   MEDLINE=94214481; PubMed=8162056; DOI=10.1093/hmg/3.1.79;
RA   Bradley L.A.D., Sweatman A.K., Lovering R.C., Jones A.M., Morgan G.,
RA   Levinsky R.J., Kinnon C.;
RT   "Mutation detection in the X-linked agammaglobulinemia gene, BTK,
RT   using single strand conformation polymorphism analysis.";
RL   Hum. Mol. Genet. 3:79-83(1994).
RN   [26]
RP   VARIANTS XLA HIS-28 AND TRP-288.
RX   MEDLINE=94214435; PubMed=8162018; DOI=10.1093/hmg/3.1.161;
RA   de Weers M., Mensink R.G.J., Kraakman M.E.M., Schuurman R.K.B.,
RA   Hendriks R.W.;
RT   "Mutation analysis of the Bruton's tyrosine kinase gene in X-linked
RT   agammaglobulinemia: identification of a mutation which affects the
RT   same codon as is altered in immunodeficient xid mice.";
RL   Hum. Mol. Genet. 3:161-166(1994).
RN   [27]
RP   VARIANTS XLA ASP-113; CYS-361; GLN-520; PRO-542; TRP-562; LYS-630 AND
RP   PRO-652.
RX   MEDLINE=95152494; PubMed=7849697; DOI=10.1093/hmg/3.10.1751;
RA   Conley M.E., Fitch-Hilgenberg M.E., Cleveland J.L., Parolini O.,
RA   Rohrer J.;
RT   "Screening of genomic DNA to identify mutations in the gene for
RT   Bruton's tyrosine kinase.";
RL   Hum. Mol. Genet. 3:1751-1756(1994).
RN   [28]
RP   VARIANTS XLA HIS-28; PRO-33; PRO-408; GLY-589; ASP-613 AND
RP   260-GLN--GLU-280 DEL.
RX   MEDLINE=95152522; PubMed=7849721; DOI=10.1093/hmg/3.10.1899;
RA   Zhu Q., Zhang M., Winkelstein J., Chen S.-H., Ochs H.D.;
RT   "Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-
RT   linked agammaglobulinemia families.";
RL   Hum. Mol. Genet. 3:1899-1900(1994).
RN   [29]
RP   VARIANTS XLA GLU-430; GLN-520; GLN-525; PRO-562; VAL-582; GLY-589;
RP   GLU-594 AND ASP-613.
RX   MEDLINE=95108046; PubMed=7809124; DOI=10.1073/pnas.91.26.12803;
RA   Vihinen M., Vetrie D., Maniar H.S., Ochs H.D., Zhu Q., Vorechovsky I.,
RA   Webster A.D.B., Notarangelo L.D., Nilsson L., Sowadski J.M.,
RA   Smith C.I.E.;
RT   "Structural basis for chromosome X-linked agammaglobulinemia: a
RT   tyrosine kinase disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:12803-12807(1994).
RN   [30]
RP   VARIANT XLA PHE-64, AND CHARACTERIZATION OF OTHER XLA VARIANTS.
RX   MEDLINE=95151728; PubMed=7849006; DOI=10.1021/bi00005a002;
RA   Vihinen M., Zvelebil J.J.M., Zhu Q., Brooimans R.A., Ochs H.D.,
RA   Zegers B.J.M., Nilsson L., Waterfield M.D., Smith C.I.E.;
RT   "Structural basis for pleckstrin homology domain mutations in X-linked
RT   agammaglobulinemia.";
RL   Biochemistry 34:1475-1481(1995).
RN   [31]
RP   VARIANTS XLA SER-25; TRP-288; MET-370; VAL-509; PRO-525; LYS-526;
RP   TRP-562; VAL-582 AND ARG-594.
RX   MEDLINE=95227177; PubMed=7711734;
RA   Vorechovsky I., Vihinen M., de Saint Basile G., Honsova S.,
RA   Hammarstroem L., Mueller S., Nilsson L., Fischer A., Smith C.I.E.;
RT   "DNA-based mutation analysis of Bruton's tyrosine kinase gene in
RT   patients with X-linked agammaglobulinaemia.";
RL   Hum. Mol. Genet. 4:51-58(1995).
RN   [32]
RP   VARIANTS XLA LYS-567; LEU-587 AND HIS-641.
RX   MEDLINE=95359977; PubMed=7633420; DOI=10.1093/hmg/4.4.693;
RA   Jin H., Webster A.D.B., Vihinen M., Sideras P., Vorechovsky I.,
RA   Hammarstroem L., Bernatowska-Matuszkiewicz E., Smith C.I.E.,
RA   Bobrow M., Vetrie D.;
RT   "Identification of Btk mutations in 20 unrelated patients with X-
RT   linked agammaglobulinaemia (XLA).";
RL   Hum. Mol. Genet. 4:693-700(1995).
RN   [33]
RP   VARIANTS XLA PRO-33; GLY-302 DEL; GLN-520 AND CYS-641.
RX   MEDLINE=95359987; PubMed=7633429; DOI=10.1093/hmg/4.4.755;
RA   Gaspar H.B., Bradley L.A.D., Katz F., Lovering R.C., Roifman C.M.,
RA   Morgan G., Levinsky R.J., Kinnon C.;
RT   "Mutation analysis in Bruton's tyrosine kinase, the X-linked
RT   agammaglobulinaemia gene, including identification of an insertional
RT   hotspot.";
RL   Hum. Mol. Genet. 4:755-757(1995).
RN   [34]
RP   VARIANTS XLA ASN-429 AND ARG-477.
RX   MEDLINE=96177680; PubMed=8634718; DOI=10.1093/hmg/4.12.2403;
RA   Vorechovsky I., Luo L., de Saint Basile G., Hammarstroem L.,
RA   Webster A.D.B., Smith C.I.E.;
RT   "Improved oligonucleotide primer set for molecular diagnosis of X-
RT   linked agammaglobulinaemia: predominance of amino acid substitutions
RT   in the catalytic domain of Bruton's tyrosine kinase.";
RL   Hum. Mol. Genet. 4:2403-2405(1995).
RN   [35]
RP   VARIANTS XLA GLU-302 AND ASP-476.
RX   MEDLINE=95353280; PubMed=7627183; DOI=10.1002/humu.1380050405;
RA   Hagemann T.L., Rosen F.S., Kwan S.-P.;
RT   "Characterization of germline mutations of the gene encoding Bruton's
RT   tyrosine kinase in families with X-linked agammaglobulinemia.";
RL   Hum. Mutat. 5:296-302(1995).
RN   [36]
RP   VARIANT XLA PHE-358.
RX   MEDLINE=95205385; PubMed=7897635;
RA   Ohashi Y., Tsuchiya S., Konno T.;
RT   "A new point mutation involving a highly conserved leucine in the Btk
RT   SH2 domain in a family with X linked agammaglobulinaemia.";
RL   J. Med. Genet. 32:77-79(1995).
RN   [37]
RP   VARIANT XLA PRO-295.
RX   MEDLINE=96298293; PubMed=8723128;
RX   DOI=10.1002/(SICI)1096-8628(19960503)63:1<318::AID-AJMG53>3.0.CO;2-N;
RA   Schuster V., Seidenspinner S., Kreth H.W.;
RT   "Detection of a novel mutation in the SRC homology domain 2 (SH2) of
RT   Bruton's tyrosine kinase and direct female carrier evaluation in a
RT   family with X-linked agammaglobulinemia.";
RL   Am. J. Med. Genet. 63:318-322(1996).
RN   [38]
RP   VARIANTS XLA ARG-12; PRO-28; GLU-302; TRP-502; HIS-521; TYR-633 AND
RP   SER-644.
RX   MEDLINE=96289505; PubMed=8695804;
RA   Hashimoto S., Tsukada S., Matsushita M., Miyawaki T., Niida Y.,
RA   Yachie A., Kobayashi S., Iwata T., Hayakawa H., Matsuoka H., Tsuge I.,
RA   Yamadori T., Kunikata T., Arai S., Yoshizaki K., Taniguchi N.,
RA   Kishimoto T.;
RT   "Identification of Bruton's tyrosine kinase (Btk) gene mutations and
RT   characterization of the derived proteins in 35 X-linked
RT   agammaglobulinemia families: a nationwide study of Btk deficiency in
RT   Japan.";
RL   Blood 88:561-573(1996).
RN   [39]
RP   VARIANTS XLA TRP-288; LYS-544 AND PRO-592.
RX   MEDLINE=96431154; PubMed=8834236; DOI=10.1007/s004390050066;
RA   Kobayashi S., Iwata T., Saito M., Iwasaki R., Matsumoto H.,
RA   Naritaka S., Kono Y., Hayashi Y.;
RT   "Mutations of the Btk gene in 12 unrelated families with X-linked
RT   agammaglobulinemia in Japan.";
RL   Hum. Genet. 97:424-430(1996).
RN   [40]
RP   VARIANTS XLA SER-154 AND ARG-155.
RX   MEDLINE=97424361; PubMed=9280283; DOI=10.1016/S0014-5793(97)00912-5;
RA   Vihinen M., Nore B., Mattsson P.T., Backesj C.-M., Nars M.,
RA   Koutaniemi S., Watanabe C., Lester T., Jones A.M., Ochs H.D.,
RA   Smith C.I.E.;
RT   "Missense mutations affecting a conserved cysteine pair in the TH
RT   domain of Btk.";
RL   FEBS Lett. 413:205-210(1997).
RN   [41]
RP   VARIANTS XLA.
RX   MEDLINE=97406776; PubMed=9260159;
RA   Saha B.K., Curtis S.K., Vogler L.B., Vihinen M.;
RT   "Molecular and structural characterization of five novel mutations in
RT   the Bruton's tyrosine kinase gene from patients with X-linked
RT   agammaglobulinemia.";
RL   Mol. Med. 3:477-485(1997).
RN   [42]
RP   VARIANTS XLA GLN-288; THR-307; ARG-430; ASP-445; GLY-525; PHE-535;
RP   LEU-563 AND PRO-622.
RX   MEDLINE=98213565; PubMed=9545398; DOI=10.1086/301828;
RA   Conley M.E., Mathias D., Treadaway J., Minegishi Y., Rohrer J.;
RT   "Mutations in btk in patients with presumed X-linked
RT   agammaglobulinemia.";
RL   Am. J. Hum. Genet. 62:1034-1043(1998).
RN   [43]
RP   VARIANTS XLA GLU-19; HIS-28; ASN-61; PRO-117; HIS-127; ARG-155;
RP   PRO-295; PHE-369; GLY-372; ARG-414; TYR-506; GLY-521; GLN-525;
RP   SER-559; TRP-562; GLU-594; THR-619; GLY-626 AND HIS-641.
RX   MEDLINE=98118357; PubMed=9445504;
RA   Holinski-Feder E., Weiss M., Brandau O., Jedele K.B., Nore B.,
RA   Baeckesjoe C.-M., Vihinen M., Hubbard S.R., Belohradsky B.H.,
RA   Smith C.I.E., Meindl A.;
RT   "Mutation screening of the BTK gene in 56 families with X-linked
RT   agammaglobulinemia (XLA): 47 unique mutations without correlation to
RT   clinical course.";
RL   Pediatrics 101:276-284(1998).
RN   [44]
RP   VARIANTS XLA.
RX   MEDLINE=99235546; PubMed=10220140;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L;
RA   Vihinen M., Kwan S.-P., Lester T., Ochs H.D., Resnick I., Vaeliaho J.,
RA   Conley M.E., Smith C.I.E.;
RT   "Mutations of the human BTK gene coding for Bruton tyrosine kinase in
RT   X-linked agammaglobulinemia.";
RL   Hum. Mutat. 13:280-285(1999).
RN   [45]
RP   VARIANT XLA PRO-562.
RX   PubMed=10678660;
RX   DOI=10.1002/(SICI)1096-8628(20000131)90:3<229::AID-AJMG8>3.0.CO;2-Q;
RA   Curtis S.K., Hebert M.D., Saha B.K.;
RT   "Twin carriers of X-linked agammaglobulinemia (XLA) due to germline
RT   mutation in the Btk gene.";
RL   Am. J. Med. Genet. 90:229-232(2000).
RN   [46]
RP   VARIANTS XLA SER-39; PRO-512; GLN-512; GLY-544; TYR-578 AND LYS-589.
RX   MEDLINE=20081066; PubMed=10612838;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<117::AID-HUMU26>3.0.CO;2-H;
RA   Orlandi P., Ritis K., Moschese V., Angelini F., Arvanitidis K.,
RA   Speletas M., Sideras P., Plebani A., Rossi P.;
RT   "Identification of nine novel mutations in the Bruton's tyrosine
RT   kinase gene in X-linked agammaglobulinaemia patients.";
RL   Hum. Mutat. 15:117-117(2000).
RN   [47]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-82 AND LYS-190.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Plays a crucial role in B-cell ontogeny. Transiently
CC       phosphorylates GTF2I on tyrosine residues in response to B-cell
CC       receptor cross-linking. Required for the formation of functional
CC       ARID3A DNA-binding complexes.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per subunit.
CC   -!- ENZYME REGULATION: Inhibited by IBTK. Activated by
CC       phosphorylation.
CC   -!- SUBUNIT: Binds GTF2I through the PH domain. Interacts with SH3BP5
CC       via the SH3 domain. Interacts with IBTK via its PH domain.
CC       Interacts with GTF2I and ARID3A.
CC   -!- INTERACTION:
CC       Self; NbExp=1; IntAct=EBI-624835, EBI-624835;
CC       P48023:FASLG; NbExp=1; IntAct=EBI-624835, EBI-495538;
CC       P30273:FCER1G; NbExp=1; IntAct=EBI-624835, EBI-515289;
CC       P78347:GTF2I; NbExp=4; IntAct=EBI-624835, EBI-359622;
CC       Q9P2D0:IBTK; NbExp=4; IntAct=EBI-624835, EBI-1052017;
CC       Q04759:PRKCQ; NbExp=2; IntAct=EBI-624835, EBI-374762;
CC       O60239:SH3BP5; NbExp=3; IntAct=EBI-624835, EBI-624860;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Membrane;
CC       Peripheral membrane protein (By similarity). Nucleus (By
CC       similarity).
CC   -!- PTM: Autophosphorylated on Tyr-223 and Tyr-551. Phosphorylation of
CC       Tyr-223 may create a docking site for a SH2 containing protein (By
CC       similarity).
CC   -!- DISEASE: Defects in BTK are the cause of X-linked
CC       agammaglobulinemia (XLA) [MIM:300755]; also known as X-linked
CC       agammaglobulinemia type 1 (AGMX1) or immunodeficiency type 1
CC       (IMD1). XLA is a humoral immunodeficiency disease which results in
CC       developmental defects in the maturation pathway of B-cells.
CC       Affected boys have normal levels of pre-B-cells in their bone
CC       marrow but virtually no circulating mature B-lymphocytes. This
CC       results in a lack of immunoglobulins of all classes and leads to
CC       recurrent bacterial infections like otitis, conjunctivitis,
CC       dermatitis, sinusitis in the first few years of life, or even some
CC       patients present overwhelming sepsis or meningitis, resulting in
CC       death in a few hours. Treatment in most cases is by infusion of
CC       intravenous immunoglobulin.
CC   -!- DISEASE: Defects in BTK may be the cause of X-linked
CC       hypogammaglobulinemia and isolated growth hormone deficiency (XLA-
CC       IGHD) [MIM:307200]; also known as agammaglobulinemia and isolated
CC       growth hormone deficiency or Fleisher syndrome or isolated growth
CC       hormone deficiency type 3 (IGHD3). In rare cases XLA is inherited
CC       together with isolated growth hormone deficiency (IGHD).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. TEC subfamily.
CC   -!- SIMILARITY: Contains 1 Btk-type zinc finger.
CC   -!- SIMILARITY: Contains 1 PH domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 SH2 domain.
CC   -!- SIMILARITY: Contains 1 SH3 domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BTKID851chXq22.html";
CC   -!- WEB RESOURCE: Name=BTKbase; Note=BTK mutation db;
CC       URL="http://bioinf.uta.fi/BTKbase/";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/BTK";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X58957; CAA41728.1; -; mRNA.
DR   EMBL; U10087; AAB60639.1; -; Genomic_DNA.
DR   EMBL; U10084; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; U10085; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; U10086; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; L31572; AAA61479.1; -; Genomic_DNA.
DR   EMBL; L31557; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31558; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31559; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31561; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31563; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31564; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31565; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31566; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31567; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31568; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31569; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31570; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31571; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; U13433; AAC51347.1; -; Genomic_DNA.
DR   EMBL; U13410; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13412; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13413; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13414; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13415; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13416; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13417; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13422; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13423; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13424; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13425; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13427; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13428; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13429; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13430; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13431; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13432; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U78027; AAB64205.1; -; Genomic_DNA.
DR   EMBL; AL035422; CAB55876.1; -; Genomic_DNA.
DR   EMBL; BC109079; AAI09080.1; -; mRNA.
DR   EMBL; BC109080; AAI09081.1; -; mRNA.
DR   IPI; IPI00029132; -.
DR   PIR; I37212; A45184.
DR   RefSeq; NP_000052.1; -.
DR   UniGene; Hs.159494; -.
DR   PDB; 1AWW; NMR; -; A=212-275.
DR   PDB; 1AWX; NMR; -; A=212-275.
DR   PDB; 1B55; X-ray; 2.40 A; A/B=2-170.
DR   PDB; 1BTK; X-ray; 1.60 A; A/B=2-170.
DR   PDB; 1BWN; X-ray; 2.10 A; A/B=2-170.
DR   PDB; 1K2P; X-ray; 2.10 A; A/B=397-659.
DR   PDB; 1QLY; NMR; -; A=216-273.
DR   PDB; 2GE9; NMR; -; A=270-386.
DR   PDB; 2Z0P; X-ray; 2.58 A; A/B/C/D=2-170.
DR   PDB; 3GEN; X-ray; 1.60 A; A=382-659.
DR   PDB; 3K54; X-ray; 1.94 A; A=382-659.
DR   PDBsum; 1AWW; -.
DR   PDBsum; 1AWX; -.
DR   PDBsum; 1B55; -.
DR   PDBsum; 1BTK; -.
DR   PDBsum; 1BWN; -.
DR   PDBsum; 1K2P; -.
DR   PDBsum; 1QLY; -.
DR   PDBsum; 2GE9; -.
DR   PDBsum; 2Z0P; -.
DR   PDBsum; 3GEN; -.
DR   PDBsum; 3K54; -.
DR   ProteinModelPortal; Q06187; -.
DR   SMR; Q06187; 130-196, 185-272, 216-651.
DR   DIP; DIP-34071N; -.
DR   IntAct; Q06187; 29.
DR   MINT; MINT-110243; -.
DR   STRING; Q06187; -.
DR   PhosphoSite; Q06187; -.
DR   PRIDE; Q06187; -.
DR   Ensembl; ENST00000308731; ENSP00000308176; ENSG00000010671.
DR   GeneID; 695; -.
DR   KEGG; hsa:695; -.
DR   UCSC; uc004ehg.1; human.
DR   CTD; 695; -.
DR   GeneCards; GC0XM100604; -.
DR   H-InvDB; HIX0016926; -.
DR   HGNC; HGNC:1133; BTK.
DR   HPA; CAB016689; -.
DR   HPA; HPA001198; -.
DR   HPA; HPA002028; -.
DR   MIM; 300300; gene.
DR   MIM; 300755; phenotype.
DR   MIM; 307200; phenotype.
DR   Orphanet; 47; X-linked agammaglobulinemia.
DR   PharmGKB; PA25454; -.
DR   eggNOG; prNOG12010; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; Q06187; -.
DR   OMA; SWEIDPK; -.
DR   OrthoDB; EOG97WR7S; -.
DR   PhylomeDB; Q06187; -.
DR   BRENDA; 2.7.10.2; 247.
DR   Pathway_Interaction_DB; bcr_5pathway; BCR signaling pathway.
DR   Pathway_Interaction_DB; pi3kcipathway; Class I PI3K signaling events.
DR   Pathway_Interaction_DB; epopathway; EPO signaling pathway.
DR   Pathway_Interaction_DB; fcer1pathway; Fc-epsilon receptor I signaling in mast cells.
DR   NextBio; 2850; -.
DR   ArrayExpress; Q06187; -.
DR   Bgee; Q06187; -.
DR   CleanEx; HS_BTK; -.
DR   Genevestigator; Q06187; -.
DR   GermOnline; ENSG00000010671; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:HGNC.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; TAS:HGNC.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kina...; IEA:EC.
DR   GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate bi...; IDA:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; TAS:HGNC.
DR   GO; GO:0008624; P:induction of apoptosis by extracellular sig...; TAS:ProtInc.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_type.
DR   InterPro; IPR001849; Pleckstrin_homology.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR020753; Tyr_kinase_non-rcpt_Btk.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR001562; Znf_Btk_motif.
DR   Gene3D; G3DSA:2.30.29.30; PH_type; 1.
DR   Gene3D; G3DSA:3.30.505.10; SH2; 1.
DR   PANTHER; PTHR23256:SF262; Tyr_kinase_non-rcpt_Btk; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF00779; BTK; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00402; TECBTKDOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00107; BTK; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF50044; SH3; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
DR   PROSITE; PS51113; ZF_BTK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Kinase; Membrane;
KW   Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    659       Tyrosine-protein kinase BTK.
FT                                /FTId=PRO_0000088065.
FT   DOMAIN        3    133       PH.
FT   DOMAIN      214    274       SH3.
FT   DOMAIN      281    377       SH2.
FT   DOMAIN      402    655       Protein kinase.
FT   ZN_FING     135    171       Btk-type.
FT   NP_BIND     408    416       ATP (By similarity).
FT   ACT_SITE    521    521       Proton acceptor (By similarity).
FT   METAL       143    143       Zinc.
FT   METAL       154    154       Zinc.
FT   METAL       155    155       Zinc.
FT   METAL       165    165       Zinc.
FT   BINDING     430    430       ATP (By similarity).
FT   MOD_RES       2      2       N-acetylalanine.
FT   MOD_RES      20     20       Phosphothreonine.
FT   MOD_RES      21     21       Phosphoserine.
FT   MOD_RES      40     40       Phosphotyrosine (By similarity).
FT   MOD_RES      55     55       Phosphoserine.
FT   MOD_RES     179    179       Phosphoserine.
FT   MOD_RES     180    180       Phosphoserine.
FT   MOD_RES     191    191       Phosphothreonine.
FT   MOD_RES     223    223       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     309    309       Phosphoserine.
FT   MOD_RES     323    323       Phosphoserine.
FT   MOD_RES     342    342       Phosphoserine.
FT   MOD_RES     344    344       Phosphotyrosine (By similarity).
FT   MOD_RES     361    361       Phosphotyrosine.
FT   MOD_RES     375    375       Phosphotyrosine.
FT   MOD_RES     551    551       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     602    602       Phosphothreonine.
FT   MOD_RES     604    604       Phosphoserine.
FT   MOD_RES     659    659       Phosphoserine.
FT   VARIANT      11     11       L -> P (in XLA).
FT                                /FTId=VAR_006216.
FT   VARIANT      12     12       K -> R (in XLA).
FT                                /FTId=VAR_006217.
FT   VARIANT      14     14       S -> F (in XLA).
FT                                /FTId=VAR_006218.
FT   VARIANT      19     19       K -> E (in XLA).
FT                                /FTId=VAR_008291.
FT   VARIANT      25     25       F -> S (in XLA).
FT                                /FTId=VAR_006219.
FT   VARIANT      27     27       K -> R (in XLA).
FT                                /FTId=VAR_008292.
FT   VARIANT      28     28       R -> C (in XLA; no effect on
FT                                phosphorylation of GTF2I).
FT                                /FTId=VAR_008293.
FT   VARIANT      28     28       R -> H (in XLA; moderate).
FT                                /FTId=VAR_006220.
FT   VARIANT      28     28       R -> P (in XLA).
FT                                /FTId=VAR_006221.
FT   VARIANT      33     33       T -> P (in XLA; severe).
FT                                /FTId=VAR_006222.
FT   VARIANT      39     39       Y -> S (in XLA).
FT                                /FTId=VAR_008960.
FT   VARIANT      40     40       Y -> C (in XLA).
FT                                /FTId=VAR_008294.
FT   VARIANT      40     40       Y -> N (in XLA).
FT                                /FTId=VAR_008295.
FT   VARIANT      61     61       I -> N (in XLA).
FT                                /FTId=VAR_008296.
FT   VARIANT      64     64       V -> D (in XLA).
FT                                /FTId=VAR_008297.
FT   VARIANT      64     64       V -> F (in XLA).
FT                                /FTId=VAR_006223.
FT   VARIANT      82     82       R -> K (in dbSNP:rs56035945).
FT                                /FTId=VAR_041676.
FT   VARIANT     103    103       Q -> QSVFSSTR (in XLA).
FT                                /FTId=VAR_006224.
FT   VARIANT     113    113       V -> D (in XLA).
FT                                /FTId=VAR_006225.
FT   VARIANT     115    115       S -> F (in XLA).
FT                                /FTId=VAR_008298.
FT   VARIANT     117    117       T -> P (in XLA).
FT                                /FTId=VAR_008299.
FT   VARIANT     127    127       Q -> H (in XLA).
FT                                /FTId=VAR_008300.
FT   VARIANT     154    154       C -> S (in XLA).
FT                                /FTId=VAR_008301.
FT   VARIANT     155    155       C -> G (in XLA).
FT                                /FTId=VAR_008302.
FT   VARIANT     155    155       C -> R (in XLA).
FT                                /FTId=VAR_008303.
FT   VARIANT     184    184       T -> P (in XLA).
FT                                /FTId=VAR_008304.
FT   VARIANT     190    190       P -> K (in a lung large cell carcinoma
FT                                sample; somatic mutation; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_041677.
FT   VARIANT     260    280       Missing (in XLA; severe).
FT                                /FTId=VAR_006226.
FT   VARIANT     288    288       R -> Q (in XLA).
FT                                /FTId=VAR_008305.
FT   VARIANT     288    288       R -> W (in XLA).
FT                                /FTId=VAR_006227.
FT   VARIANT     295    295       L -> P (in XLA).
FT                                /FTId=VAR_006228.
FT   VARIANT     302    302       G -> E (in XLA).
FT                                /FTId=VAR_006230.
FT   VARIANT     302    302       G -> R (in XLA).
FT                                /FTId=VAR_008306.
FT   VARIANT     302    302       Missing (in XLA).
FT                                /FTId=VAR_006229.
FT   VARIANT     307    307       R -> G (in XLA; loss of activity).
FT                                /FTId=VAR_006231.
FT   VARIANT     307    307       R -> T (in XLA).
FT                                /FTId=VAR_008307.
FT   VARIANT     308    308       D -> E (in XLA).
FT                                /FTId=VAR_008308.
FT   VARIANT     319    319       V -> A (in XLA; moderate).
FT                                /FTId=VAR_008309.
FT   VARIANT     334    334       Y -> S (in XLA).
FT                                /FTId=VAR_006232.
FT   VARIANT     358    358       L -> F (in XLA).
FT                                /FTId=VAR_006233.
FT   VARIANT     361    361       Y -> C (in XLA; mild; dbSNP:rs28935478).
FT                                /FTId=VAR_006234.
FT   VARIANT     362    362       H -> Q (in XLA).
FT                                /FTId=VAR_006235.
FT   VARIANT     364    364       H -> P (in XLA).
FT                                /FTId=VAR_006236.
FT   VARIANT     365    365       N -> Y (in XLA).
FT                                /FTId=VAR_006237.
FT   VARIANT     366    366       S -> F (in XLA).
FT                                /FTId=VAR_008310.
FT   VARIANT     369    369       L -> F (in XLA).
FT                                /FTId=VAR_008311.
FT   VARIANT     370    370       I -> M (in XLA).
FT                                /FTId=VAR_006238.
FT   VARIANT     372    372       R -> G (in XLA).
FT                                /FTId=VAR_008312.
FT   VARIANT     408    408       L -> P (in XLA; moderate).
FT                                /FTId=VAR_006239.
FT   VARIANT     414    414       G -> R (in XLA).
FT                                /FTId=VAR_008313.
FT   VARIANT     418    418       Y -> H (in XLA).
FT                                /FTId=VAR_006240.
FT   VARIANT     429    429       I -> N (in XLA).
FT                                /FTId=VAR_006241.
FT   VARIANT     430    430       K -> E (in XLA; loss of phosphorylation
FT                                of GTF2I).
FT                                /FTId=VAR_006242.
FT   VARIANT     430    430       K -> R (in XLA).
FT                                /FTId=VAR_008314.
FT   VARIANT     445    445       E -> D (in XLA).
FT                                /FTId=VAR_008315.
FT   VARIANT     462    462       G -> D (in XLA).
FT                                /FTId=VAR_008316.
FT   VARIANT     462    462       G -> V (in XLA).
FT                                /FTId=VAR_008317.
FT   VARIANT     476    476       Y -> D (in XLA).
FT                                /FTId=VAR_006243.
FT   VARIANT     477    477       M -> R (in XLA).
FT                                /FTId=VAR_006244.
FT   VARIANT     502    502       C -> F (in XLA).
FT                                /FTId=VAR_006245.
FT   VARIANT     502    502       C -> W (in XLA).
FT                                /FTId=VAR_006246.
FT   VARIANT     506    506       C -> R (in XLA).
FT                                /FTId=VAR_006247.
FT   VARIANT     506    506       C -> Y (in XLA).
FT                                /FTId=VAR_006248.
FT   VARIANT     508    508       A -> D (in XLA).
FT                                /FTId=VAR_008318.
FT   VARIANT     509    509       M -> I (in XLA).
FT                                /FTId=VAR_008319.
FT   VARIANT     509    509       M -> V (in XLA).
FT                                /FTId=VAR_006249.
FT   VARIANT     512    512       L -> P (in XLA).
FT                                /FTId=VAR_008961.
FT   VARIANT     512    512       L -> Q (in XLA).
FT                                /FTId=VAR_008962.
FT   VARIANT     518    518       L -> R (in XLA).
FT                                /FTId=VAR_008320.
FT   VARIANT     520    520       R -> Q (in XLA; severe; prevents
FT                                activation due to absence of contact
FT                                between the catalytic loop and the
FT                                regulatory phosphorylated residue).
FT                                /FTId=VAR_006251.
FT   VARIANT     521    521       D -> G (in XLA).
FT                                /FTId=VAR_008321.
FT   VARIANT     521    521       D -> H (in XLA; severe).
FT                                /FTId=VAR_006252.
FT   VARIANT     521    521       D -> N (in XLA; severe).
FT                                /FTId=VAR_006253.
FT   VARIANT     523    523       A -> E (in XLA).
FT                                /FTId=VAR_008322.
FT   VARIANT     525    525       R -> G (in XLA).
FT                                /FTId=VAR_008323.
FT   VARIANT     525    525       R -> P (in XLA).
FT                                /FTId=VAR_006254.
FT   VARIANT     525    525       R -> Q (in XLA; severe; disturbs ATP-
FT                                binding).
FT                                /FTId=VAR_006255.
FT   VARIANT     526    526       N -> K (in XLA).
FT                                /FTId=VAR_006256.
FT   VARIANT     535    535       V -> F (in XLA).
FT                                /FTId=VAR_008324.
FT   VARIANT     542    542       L -> P (in XLA; growth hormone
FT                                deficiency).
FT                                /FTId=VAR_006257.
FT   VARIANT     544    544       R -> G (in XLA).
FT                                /FTId=VAR_008963.
FT   VARIANT     544    544       R -> K (in XLA).
FT                                /FTId=VAR_006258.
FT   VARIANT     559    559       F -> S (in XLA).
FT                                /FTId=VAR_008325.
FT   VARIANT     562    562       R -> P (in XLA; dbSNP:rs28935176).
FT                                /FTId=VAR_006259.
FT   VARIANT     562    562       R -> W (in XLA).
FT                                /FTId=VAR_006260.
FT   VARIANT     563    563       W -> L (in XLA).
FT                                /FTId=VAR_008326.
FT   VARIANT     567    567       E -> K (in XLA; severe).
FT                                /FTId=VAR_006261.
FT   VARIANT     578    578       S -> Y (in XLA).
FT                                /FTId=VAR_008964.
FT   VARIANT     581    581       W -> R (in XLA).
FT                                /FTId=VAR_006262.
FT   VARIANT     582    582       A -> V (in XLA).
FT                                /FTId=VAR_006263.
FT   VARIANT     583    583       F -> S (in XLA).
FT                                /FTId=VAR_008327.
FT   VARIANT     587    587       M -> L (in XLA; mild).
FT                                /FTId=VAR_006264.
FT   VARIANT     589    589       E -> D (in XLA).
FT                                /FTId=VAR_008328.
FT   VARIANT     589    589       E -> G (in XLA; moderate; interferes with
FT                                substrate binding).
FT                                /FTId=VAR_006265.
FT   VARIANT     589    589       E -> K (in XLA).
FT                                /FTId=VAR_008965.
FT   VARIANT     592    592       S -> P (in XLA).
FT                                /FTId=VAR_006267.
FT   VARIANT     594    594       G -> E (in XLA; mild; interferes with
FT                                substrate binding).
FT                                /FTId=VAR_006268.
FT   VARIANT     594    594       G -> R (in XLA).
FT                                /FTId=VAR_006269.
FT   VARIANT     598    598       Y -> C (in XLA).
FT                                /FTId=VAR_006270.
FT   VARIANT     607    607       A -> D (in XLA; mild).
FT                                /FTId=VAR_006271.
FT   VARIANT     613    613       G -> D (in XLA; mild; interferes with
FT                                substrate binding and/or domain
FT                                interactions).
FT                                /FTId=VAR_006272.
FT   VARIANT     619    619       P -> A (in XLA).
FT                                /FTId=VAR_008330.
FT   VARIANT     619    619       P -> S (in XLA).
FT                                /FTId=VAR_006273.
FT   VARIANT     619    619       P -> T (in XLA).
FT                                /FTId=VAR_008331.
FT   VARIANT     622    622       A -> P (in XLA).
FT                                /FTId=VAR_008332.
FT   VARIANT     626    626       V -> G (in XLA).
FT                                /FTId=VAR_008333.
FT   VARIANT     630    630       M -> I (polymorphism, 35%).
FT                                /FTId=VAR_006274.
FT   VARIANT     630    630       M -> K (in XLA).
FT                                /FTId=VAR_006275.
FT   VARIANT     630    630       M -> T (in XLA).
FT                                /FTId=VAR_008334.
FT   VARIANT     633    633       C -> Y (in XLA).
FT                                /FTId=VAR_006276.
FT   VARIANT     641    641       R -> C (in XLA).
FT                                /FTId=VAR_006277.
FT   VARIANT     641    641       R -> H (in XLA; severe).
FT                                /FTId=VAR_006278.
FT   VARIANT     644    644       F -> L (in XLA).
FT                                /FTId=VAR_008335.
FT   VARIANT     644    644       F -> S (in XLA).
FT                                /FTId=VAR_006279.
FT   VARIANT     647    647       L -> P (in XLA).
FT                                /FTId=VAR_006280.
FT   VARIANT     652    652       L -> P (in XLA).
FT                                /FTId=VAR_006281.
FT   MUTAGEN      41     41       E->K: No effect on phosphorylation of
FT                                GTF2I.
FT   MUTAGEN     189    189       P->A: No effect on phosphorylation of
FT                                GTF2I.
FT   MUTAGEN     223    223       Y->F: Loss of phosphorylation of GTF2I.
FT   MUTAGEN     251    252       WW->LL: Large decrease in binding by
FT                                SH3BP5.
FT   MUTAGEN     251    251       W->L: No effect on phosphorylation of
FT                                GTF2I.
FT   MUTAGEN     307    307       R->K: Loss of phosphorylation of GTF2I.
FT   MUTAGEN     551    551       Y->F: Loss of phosphorylation of GTF2I.
FT   STRAND        5     13
FT   STRAND       25     32
FT   STRAND       34     43
FT   TURN         44     47
FT   STRAND       48     57
FT   STRAND       60     66
FT   HELIX        75     77
FT   HELIX        90     93
FT   TURN         94     96
FT   STRAND      100    106
FT   STRAND      109    117
FT   HELIX       118    132
FT   STRAND      140    142
FT   TURN        153    155
FT   STRAND      165    167
FT   TURN        212    215
FT   STRAND      218    221
FT   STRAND      228    232
FT   STRAND      240    243
FT   STRAND      248    255
FT   STRAND      261    265
FT   TURN        266    268
FT   STRAND      279    282
FT   HELIX       288    298
FT   STRAND      303    308
FT   STRAND      310    312
FT   STRAND      315    326
FT   STRAND      330    335
FT   STRAND      337    339
FT   TURN        340    342
FT   STRAND      343    347
FT   STRAND      350    354
FT   HELIX       355    363
FT   STRAND      373    376
FT   STRAND      414    421
FT   TURN        422    424
FT   STRAND      425    437
FT   HELIX       439    450
FT   STRAND      460    464
FT   STRAND      467    475
FT   HELIX       482    487
FT   HELIX       489    491
FT   HELIX       495    514
FT   HELIX       524    526
FT   STRAND      527    529
FT   STRAND      535    537
FT   STRAND      547    550
FT   HELIX       561    563
FT   HELIX       566    571
FT   HELIX       576    591
FT   TURN        597    600
FT   HELIX       603    611
FT   HELIX       624    632
FT   HELIX       638    640
FT   HELIX       644    652
SQ   SEQUENCE   659 AA;  76281 MW;  DF06B5D1FEC257CC CRC64;
     MAAVILESIF LKRSQQKKKT SPLNFKKRLF LLTVHKLSYY EYDFERGRRG SKKGSIDVEK
     ITCVETVVPE KNPPPERQIP RRGEESSEME QISIIERFPY PFQVVYDEGP LYVFSPTEEL
     RKRWIHQLKN VIRYNSDLVQ KYHPCFWIDG QYLCCSQTAK NAMGCQILEN RNGSLKPGSS
     HRKTKKPLPP TPEEDQILKK PLPPEPAAAP VSTSELKKVV ALYDYMPMNA NDLQLRKGDE
     YFILEESNLP WWRARDKNGQ EGYIPSNYVT EAEDSIEMYE WYSKHMTRSQ AEQLLKQEGK
     EGGFIVRDSS KAGKYTVSVF AKSTGDPQGV IRHYVVCSTP QSQYYLAEKH LFSTIPELIN
     YHQHNSAGLI SRLKYPVSQQ NKNAPSTAGL GYGSWEIDPK DLTFLKELGT GQFGVVKYGK
     WRGQYDVAIK MIKEGSMSED EFIEEAKVMM NLSHEKLVQL YGVCTKQRPI FIITEYMANG
     CLLNYLREMR HRFQTQQLLE MCKDVCEAME YLESKQFLHR DLAARNCLVN DQGVVKVSDF
     GLSRYVLDDE YTSSVGSKFP VRWSPPEVLM YSKFSSKSDI WAFGVLMWEI YSLGKMPYER
     FTNSETAEHI AQGLRLYRPH LASEKVYTIM YSCWHEKADE RPTFKILLSN ILDVMDEES
//
